Involvement of the bufodienolides in the diagnosis and treatment of post-traumatic stress disorder (ptsd)
OwnerJules B. Puschettinventor
Life of this patent
Estimating the term…
Abstract
The method of this invention relates a method of diagnosing a patient as having post-traumatic stress disorder (PTSD) and/or treating the patient therapeutically for PTSD. In one embodiment, the treatment involves administering a therapeutically effective amount of bufodienolide antagonist to the patient.
Claims16
A method of identifying a patient at risk of developting Post-Traumatic Stress Disorder (PTSD), comprising:
- obtaining a sample from the patient;
- measuring the level of marinobufagenin in the sample, wherein elevation of the level of marinobufagenin in the sample relative to a reference level is indicative of a propensity for PTSD in the patient.
A method of treating a patient who has been diagnosed as having or is at risk of developing Post-Traumatic Stress Disorder (PTSD) comprising, administering to the patient a therapeutically effective dose of a marinobufagenin (MBG) antagonist.
A method of reducing the risk of PTSD in a patient who is suspected to have a propensity for developing PTSD, comprising administering to the patient a therapeutically effective amount of a MBG antagonist.
Dependencies are inferred from the claim text.